Therapie der diabetischen Neuropathie

Schlüsselwörter

Diabetes mellitus - diabetische Neuropathie - Polyneuropathie - Schmerztherapie

Key words

diabetes mellitus - diabetic neuropathy - polyneuropathy - treatment of neuropathic pain

Literatur

• 1 Backonja M, Beydoun A, Edwards K R, Schwartz S L, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.  J Am Med Assoc. 1998;  280 1831-1836
• 2 Bierhaus A, Haslbeck K M, Humpert P M, Liliensiek B, Dehmer T, Morcos M, Sayed A A, Andrassy M, Schiekofer S, Schneider J G. et al . Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.  J Clin Invest. 2004;  114 1741-1751
• 3 Bierhaus A, Humpert P M, Morcos M, Wendt T, Chavakis T, Arnold B, Stern D M, Nawroth P P. Understanding RAGE, the receptor for advanced glycation end products.  J Mol Med. 2005;  83 876-886
• 4 Bierhaus A, Humpert P M, Rudofsky G, Wendt T, Morcos M, Hamann A, Nawroth P P. New treatments for diabetic neuropathy: pathogenetically oriented treatment.  Curr Diab Rep. 2003;  3 452-458
• 5 Bosi E, Conti M, Vermigli C, Cazzetta G, Peretti E, Cordoni M C, Galimberti G, Scionti L. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy.  Diabetologia. 2005;  48 817-823
• 6 Boulton A J, Vinik A I, Arezzo J C, Bril V, Feldman E L, Freeman R, Malik R A, Maser R E, Sosenko J M, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association.  Diabetes Care. 2005;  28 956-962
• 7 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism.  Diabetes. 2005;  54 1615-1625
• 8 Daousi C, MacFarlane I A, Woodward A, Nurmikko T J, Bundred P E, Benbow S J. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes.  Diabet Med. 2004;  21 976-982
• 9 Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes.  Diabetes Care. 2006;  29 1518-1522
• 10 Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study.  Eur J Pain. 2005;  9 543-554
• 11 Eichberg J. Protein kinase C changes in diabetes: is the concept relevant to neuropathy?.  Int Rev Neurobiol. 2002;  50 61-82
• 12 Finnerup N B, Otto M, McQuay H J, Jensen T S, Sindrup S H. Algorithm for neuropathic pain treatment: an evidence based proposal.  Pain. 2005;  118 289-305
• 13 Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa J C. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes.  Mol Pharmacol. 1995;  48 825-834
• 14 Gilron I, Bailey J M, Tu D, Holden R R, Weaver D F, Houlden R L. Morphine, gabapentin, or their combination for neuropathic pain.  N Engl J Med. 2005;  352 1324-1334
• 15 Gimbel J S, Richards P, Portenoy R K. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial.  Neurology. 2003;  60 927-934
• 16 Goldstein D J, Lu Y, Detke M J, Lee T C, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy.  Pain. 2005;  116 109-118
• 17 Griesing T, Freeman R, Rosenstock J, Sharma U, LaMoreaux L, Emir B, Siffert J. Efficacy, safety, and tolerability of pregabalin treatment for diabetic peripheral neuropathy: findings from 6 randomized controlled trials.  Diabetologia. 2005;  48 (suppl 1) A351
• 18 Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu C O. et al . Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.  Neurology. 1998;  50 1842-1846
• 19 Haslbeck M, Luft D, Neundörfer B, Stracke H, Ziegler D. Diagnostik, Therapie und Verlaufskontrolle der Neuropathie bei Diabetes mellitus Typ 1 und Typ 2. http://wwwdeutsche-diabetes-gesellschaftde/redaktion/mitteilungen/leitlinien/Leitlinie_ neuropathiepdf 2006
• 20 Ho E C, Lam K S, Chen Y S, Yip J C, Arvindakshan M, Yamagishi S, Yagihashi S, Oates P J, Ellery C A, Chung S S. et al . Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.  Diabetes. 2006;  55 1946-1953
• 21 Jensen T S, Backonja M M, Hernandez Jimenez S, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain.  Diab Vasc Dis Res. 2006;  3 108-119
• 22 Mason L, Moore R A, Derry S, Edwards J E, McQuay H J. Systematic review of topical capsaicin for the treatment of chronic pain.  Bmj. 2004;  328 991-995
• 23 Obrosova I G. How does glucose generate oxidative stress in peripheral nerve?.  Int Rev Neurobiol. 2002;  50 3-35
• 24 Raskin J, Pritchett Y L, Wang F, D’Souza D N, Waninger A L, Iyengar S, Wernicke J F. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.  Pain Med. 2005;  6 346-356
• 25 Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation.  Diabetologia. 2005;  48 824-828
• 26 Thienel U, Neto W, Schwabe S K, Vijapurkar U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials.  Acta Neurol Scand. 2004;  110 221-231
• 27 Vincent A M, Russell J W, Low P, Feldman E L. Oxidative stress in the pathogenesis of diabetic neuropathy.  Endocr Rev. 2004;  25 612-628
• 28 Vinik A I, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, Quessy S, Blum D, Grainger J, White J. et al . Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies.  Pain. 2007;  128 169-179
• 29 Vinik A I, Vinik E. Prevention of the complications of diabetes.  Am J Manag Care. 2003;  (3 Suppl) 9 S63-80; quiz S81 - 64
• 30 Wernicke J F, Pritchett Y L, D’Souza D N, Waninger A, Tran P, Iyengar S, Raskin J. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.  Neurology. 2006;  67 1411-1420
• 31 Ziegler D, Ametov A, Barinov A, Dyck P J, Gurieva I, Low P A, Munzel U, Yakhno N, Raz I, Novosadova M. et al . Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.  Diabetes Care. 2006;  29 2365-2370
• 32 Ziegler D, Nowak H, Kempler P, Vargha P, Low P A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.  Diabet Med. 2004;  21 114-121
• 33 Ziegler D, Pritchett Y L, Wang F, Desaiah D, Robinson M, Hall J, Chappell A. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.  Diabetes Care. 2007;  30 664-669
• 34 Ziegler D. Treatment of diabetic polyneuropathy: Update 2006.  Ann N Y Acad Sci. 2006;  1084 250-266
• 35 Hammes H P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P P, Hannak D, Neumeier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three Major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.  Nat Med. 2003;  9 294-299